Glycomacropeptide medical foods for nutritional management of phenylketonuria and other metabolic disorders

US10258074B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10258074-B2
Application numberUS-201414274253-A
CountryUS
Kind codeB2
Filing dateMay 9, 2014
Priority dateJun 12, 2009
Publication dateApr 16, 2019
Grant dateApr 16, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Medical foods containing glycomacroprotein and additional supplemented amounts of arginine, leucine, and optionally other amino acids, such as tyrosine, are disclosed. The medical foods can be used to provide the complete protein requirements for patients having metabolic disorders such as phenylketonuria.

First claim

Opening claim text (preview).

We claim: 1. A medical food for the management of a metabolic disorder, comprising glycomacropeptide (GMP) and two or more supplemental amino acids, wherein: (a) the total weight of the supplemental amino acids is from about 22% to 38% of the total weight of the protein from the GMP and the supplemental amino acids together; and (b) one of the supplemental amino acids is arginine and the weight ratio within the medical food of the amino acid arginine to total protein from the GMP and the supplemental amino acids together is from about 60 to 90 milligrams arginine/gram total protein. 2. The medical food of claim 1 , wherein the medical food does not contain a supplemented amount of the amino acid tyrosine. 3. The medical food of claim 1 , wherein the medical food is in the form of a beverage, a bar, a wafer, a pudding, a gelatin, a cracker, a fruit leather, a nut butter, a sauce, a salad dressing, a crisp cereal piece, a flake, a puff, a pellet, or an extruded solid. 4. The medical food of claim 1 , wherein the two or more supplemental amino acids comprise two or more amino acids selected from the group consisting of arginine, leucine, tyrosine, tryptophan, and histidine. 5. The medical food of claim 4 , wherein the two or more supplemental amino acids comprise arginine and leucine. 6. The medical food of claim 4 , wherein the two or more supplemental amino acids comprise tyrosine. 7. A method of making a medical food for the management of a metabolic disorder, the method comprising the step of mixing glycomacropeptide (GMP) and two or more supplemental amino acids to make a food, wherein: (a) the total weight of the supplemental amino acids is from about 22% to 38% of the total weight of the protein from the GMP and the supplemental amino acids together; and (b) one of the supplemental amino acids is arginine and the weight ratio within the medical food of the amino acid arginine to total protein from the GMP and the supplemental amino acids together is from about 60 to 90 milligrams arginine/gram total protein. 8. The method of claim 7 , wherein the two or more supplemental amino acids comprise two or more amino acids selected from the group consisting of arginine, leucine, tyrosine, tryptophan, and histidine. 9. The method of claim 7 , wherein the two or more supplemental amino acids comprise arginine and leucine. 10. The method of claim 7 , wherein the two or more supplemental amino acids do not comprise tyrosine. 11. A method of treating a metabolic disorder, comprising administering to a human having a metabolic disorder a medical food comprising glycomacropeptide (GMP) and two or more supplemental amino acids, wherein the metabolic disorder is selected from a Phenylalanine metabolism disorder, a Tyrosine metabolism disorder, a Tryptophan metabolism disorder, and a Histidine metabolism disorder, and wherein: (a) the total weight of the supplemental amino acids in the medical food is from about 22% to 38% of the total weight of the protein from the GMP and the supplemental amino acids together; and (b) one of the supplemental amino acids is arginine and the weight ratio within the medical food of the amino acid arginine to total protein from the GMP and the supplemental amino acids together is from about 60 to 90 milligrams arginine/gram total protein. 12. The method of claim 11 , wherein the two or more supplemental amino acids comprise arginine and leucine. 13. The method of claim 11 , wherein the two or more supplemental amino acids do not comprise tyrosine. 14. The method of claim 13 , wherein the metabolic disorder is a Tyrosine metabolism disorder.

Assignees

Inventors

Classifications

  • for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

  • Nutrients, e.g. vitamins, minerals · CPC title

  • Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title

  • A23L33/17Primary

    Amino acids, peptides or proteins · CPC title

  • A61K38/018Primary

    from milk · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10258074B2 cover?
Medical foods containing glycomacroprotein and additional supplemented amounts of arginine, leucine, and optionally other amino acids, such as tyrosine, are disclosed. The medical foods can be used to provide the complete protein requirements for patients having metabolic disorders such as phenylketonuria.
Who is the assignee on this patent?
Wisconsin Alumni Res Found, Wisonsin Alumni Res Foundation
What technology area does this patent fall under?
Primary CPC classification A23L33/17. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).